---
title: "KHB released its performance for the first half of the year, with a net loss attributable to the parent company of 133 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254587455.md"
description: "According to the Zhitong Finance APP, KHB released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 794 million yuan, a year-on-year decrease of 12.65%. The net loss attributable to shareholders of the listed company was 133 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 140 million yuan, with a basic loss per share of 0.2595 yuan"
datetime: "2025-08-26T09:27:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254587455.md)
  - [en](https://longbridge.com/en/news/254587455.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254587455.md)
---

# KHB released its performance for the first half of the year, with a net loss attributable to the parent company of 133 million yuan

According to the Zhitong Finance APP, KHB (002022.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 794 million yuan, a year-on-year decrease of 12.65%. The net loss attributable to shareholders of the listed company was 133 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 140 million yuan, with a basic loss per share of 0.2595 yuan

### Related Stocks

- [002022.CN](https://longbridge.com/en/quote/002022.CN.md)

## Related News & Research

- [Frozen blueberries recall categorized under FDA's highest Class I risk level](https://longbridge.com/en/news/296506599.md)
- [Curql invests in pet healthcare platform Wagmo](https://longbridge.com/en/news/296396050.md)
- [BUZZ-Faeth Therapeutics rises after FDA grants fast-track status for cancer drug](https://longbridge.com/en/news/296104768.md)
- [09:02 ETEvolved By Nature's Peptide Platform Used in FDA-Cleared Prescription Therapy for the Management of Atopic Dermatitis](https://longbridge.com/en/news/296496101.md)
- [Mahle Introduces Range Extender For Electric Trucks](https://longbridge.com/en/news/296523804.md)